Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27N5O5.ClH |
| Molecular Weight | 441.909 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
InChI
InChIKey=YPVGGQKNWAKOPX-UHFFFAOYSA-N
InChI=1S/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H27N5O5 |
| Molecular Weight | 405.4482 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/16157956
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/16157956
Nifekalant is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia. It has the brand name Shinbit. It is a nonselective K+ channel blocker without any β-blocking actions. Administration of nifekalant suppressed sustained ventricular tachyarrhythmias in acute coronary syndrome patients, and in cardiac arrest victims as well as during or after cardiac surgery. The major adverse effect of nifekalant is QT interval prolongation and occurrence of torsades de pointes which requires frequent monitoring of the QT interval during nifekalant infusion with adequate dose adjustment.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pretreatments with a novel pure potassium channel blocker, Nifekalant, were effective in the electrical atrial defibrillation: a report of two cases. | 2002 Dec |
|
| Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action. | 2002 Dec 13 |
|
| Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia. | 2004 Nov |
|
| Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae. | 2005 Jun |
|
| Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. | 2005 Oct |
|
| [Strategy for cardiac arrhythmias in acute coronary syndrome]. | 2006 Apr |
|
| Destabilization and early termination of spiral-wave reentry by a class III antiarrhythmic agent, nifekalant, in a perfused two-dimensional layer of rabbit ventricular myocardium. | 2006 Feb 17 |
|
| Reduced inotropic effect of nifekalant in failing hearts in rats. | 2006 Sep |
|
| Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart. | 2007 Feb |
|
| [Successful use of intravenous amiodarone for refractory ventricular fibrillation just after releasing aortic cross-clamp]. | 2010 Oct |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
For acute coronary syndrome treatment the mean dose level of nifekalant was 0.19 ± 0.14 mg/kg body weight per hour;
For peri-operative Ventricular tachyarrhythmia treatment - intravenous administration of nifekalant in a dose of 0.3 mg/kg;
For cardiopulmonary resuscitation treatment - 0.15-0.3 mg/kg followed by intravenous infusion of 0.3-0.4 mg/kg per hour as antiarrhythmic therapy
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:37:35 GMT 2023
by
admin
on
Sat Dec 16 01:37:35 GMT 2023
|
| Record UNII |
TPP5R0MDQS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000086472
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
122188
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
TPP5R0MDQS
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
C076259
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
DTXSID7048374
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
m7884
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
130656-51-8
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY | |||
|
SUB20699
Created by
admin on Sat Dec 16 01:37:35 GMT 2023 , Edited by admin on Sat Dec 16 01:37:35 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
